ANRS CO22 HEPATHER Cohort

Size: px
Start display at page:

Download "ANRS CO22 HEPATHER Cohort"

Transcription

1 ANRS CO22 HEPATHER Cohort THERAPEUTIC OPTION FOR HEPATITIS B AND C: A FRENCH NATIONWIDE COHORT STUDY

2 Public partners Private partners Public/Private Partnership management :

3 Hepatitis context in France : early access program ATU in October ATU in December ATU in March ATU in November ATU in December Sofosbuvir Sovaldi Simeprevir Olysio Daclatasvir Daklinza Sofosbuvir Ledipasvir Harvoni Paritaprevir Ombitasvir Viekirax Dasabuvir Exviera Restricted to «priority» patients F3F4 -> F2F3F4 Symptomatic cryoglobulinemic vasculitis -> All extrahepatic manifestations Waiting for liver or renal transplantation After liver transplantation -> Genotype 3 infection -> High risk of transmission

4 26/07/2013 ANRS CO22 HEPATHER COHORT SUMMARY May 31st, 2015 OBJECTIVES To describe progression of chronic HCV and HBV infections on the long term and to identify associated prognosis factors (including biomarkers). To compare the clinical and cost effectiveness and safety of treatments in «real life» To provide resources for researches in tailored HCV or HBV subpopulations Inclusion Follow up ( HBV & HCV) Patients 8 years follow-up, 32 clinical centers GENERAL APPROACH TO DATA COLLECTION AND FOLLOW-UP Centralized Biobank (blood, urine) at inclusion Clinical follow-up by interval: 1 to 2 yearly visits according to the status «A la carte» clinical follow-up : Treatment initiation, Clinical event Follow-up by individual matching on medico-administrative database (SNIIRAM, CEPI-DC) May 31st, ,691 enrolled - 12,418 HCV with 4170 HCV treated after inclusion HBV 4

5 ANRS CO22 HEPATHER Cohort : Challenges in settingup a Public-Private Partnership The scientific value and the public health improvement must be the main incentive (No pure marketing studies). Involve industrial partners in the definition of data / samples collection for align, in a certain extent, the objectives / expectations of partners. Integrate industrial partner(s) from the start and all along the project. Share the relative risk on ongoing project Protect the integrity of professional judgment and preserve public trust

6 Governance External Scientific Committee Inserm Ethic Committee Advisory Industrial Committee Gold and Platinum partners Plenary session : With industrial partners representative General Council Directed by ANRS Limited session : - ANRS, Inserm, ITM0 Santé Publique - Public Partners - Institution representative Advisory Institutional Committee AFEF, HAS, InVS, ANSM, DGS Scientific Committee (observatory INDUSTRIAL members) S. Pol (Alternate : H. Fontaine) / F. Carrat Executive Committee S. Pol (Alternate : H. Fontaine) / F. Carrat Virology F. Zoulim JM. Pawlotsky Pathology & Physiopathology P. Nahon J.Capeau Therapeutic M. Bourlière D. Larrey P. Marcellin Public Health C. Larsen P. Carrieri Sponsor Inserm- ANRS Partnership Management Inserm Transfert Investigators Database & Biobank UMR S1136/ F Carrat

7 ANRS CO22 HEPATHER Cohort : partnership philosophy The willing of Hepather s partnership is to follow the drugs life: development and launch onto the market. Two levels of partnership have been defined : GOLD partners Having specific rights in terms of PLATINUM partners 1. Hepather data access (database, biobank) 2. IP and exploitation Rights on results 3. Position in the governance 5 years commitment is request to ensure the viability and durability of Hepather. Two principles for the partnership functioning: The older partners will be privileged. The bigger partners (cumulated funding over the years) will be privileged.

8 ANRS CO22 HEPATHER Cohort : How PPP works? Inclusion of HBV or HCV infected patients ( HBV; HCV) 60% naives; 10% healing; 40% under treatment 32 centers. HEPATHER Platform Patient Data: Clinical, biological, treatment, environmental and social data Samples: Blood, serum and urine Specific Research Projects Database Raw data gathering Biobank Collection of the samples in Cell&Co Patient Dashboard characteristics of patients class, treatments Product Dashboard pharmaco-epidemio, undesirable events

9 ANRS CO22 HEPATHER Cohort : Which modalities of partnership? Platinum Partners Gold Partners Annual report Patients Dashboard (characteristics of patients class, treatments ) Products Dashboard which provides data on patients profiles under platinum partner product, effectiveness and safety outcomes,... 2 specific research projects (SRP) per year Biobank specific access fees (to be added to SRP related costs) + 1 specific research project per year Including Postmarketing studies based on Hepather data No Biobank specific access fees (only additional costs related to SRP) HAS approval of a mock-up protocol

10 ANRS CO22 HEPATHER Cohort : Industrial partners point of view ORGANIZATION Governance well organized with dedicated bodies to operational, strategic & scientific aspects independent scientific evaluation every 3 years A scientific expert network through Scientific Committee organized in thematic axis allowing to enhance international renown Complex structure slowing cohort exploitation by Industrial Partners METHODOLOGY Numerous patients enrolled in the cohort (25 000) giving access to sub-group analysis Linkage with medico-economic databases (such as SNIIRAM) Real life data generation interesting to study sub-group of patients who are not enrolled in clinical trials Biobank with a high-quality phenotyping level HEALTH AUTHORITIES Allowed post-marketing studies (pre-approved protocol by HAS) PV and/or Drug/Drug interaction studies Scientific guarantee INTERNATIONAL VISIBILITY Through its magnitude, its label (Investissements d avenir), its sponsor (ANRS), its experts network, contributing to French attractiveness Collaborations with French and European cohorts Complex structure not easy to set up (delay in clinical center opening, in enrollment, and in first exploitable data generation) Study cohort representativeness (mainly regarding the bias introduced through an enrollment in an expert center) Enhance Hepather visibility for EMA (especially for conditional marketing authorization)

11 Acknowledgments Laurent Alric, Toulouse Fabien Zoulim, Lyon François Raffi, Nantes Paul Cales, Angers Patrick Marcellin, Clichy Stanislas Pol, Paris Victor De Ledinghen, Bordeaux Marc Bourlière, Marseille Albert Tran, Nice Yves Benhamou, Paris Xavier Causse, Orléans Jean-Claude Trinchet, Jean Verdier Dominique Guyader, Rennes François Habersetzer, Strasbourg Jean-Pierre Bronowicki, Nancy Dominique Larrey, Montpellier Sophie Métivier, Toulouse Imane Amri Marc Bourlière Patrice Cacoub Jacqueline Capeau Fabrice Carrat Patrizia Carrieri Victor De Ledinghen Céline Dorival-Mouly ALL THE PATIENTS INVESTIGATORS AND COLLABORATORS SCIENTIFIC COMITTEE Jean Dubuisson Hélène Fontaine Dominique Larrey Christine Larsen Marianne L'Henaff Patrick Marcellin Philippe Mathurin Pierre Nahon Jean-Pierre Zarski, Grenoble Ghassan Riachi, Rouen Christophe Hézode, Créteil Olivier Chazouillères, Saint Antoine Didier Samuel, Paul Brousse Armand Abergel, Clermont-Ferrand Brigitte Le Guillou, Metz Isabelle Rosa, Créteil Véronique Loustaud-Ratti, Limoges Philippe Mathurin, Lille Anne Minello, Dijon Louis D'Alteroche, Tours Jérome Gourney, Nantes Isabelle Portal, Marseille Eric Saillard, Pointe à Pître Francesco Negro George-Philippe Pageaux Jean-Michel Pawlotsky Ventzislava Petrov- Sanchez Stanislas Pol Michelle Sizorn Jean-Claude Trinchet Linda Wittkop Yazdan Yazdanpanah Jean-Pierre Zarski Fabien Zoulim The ANRS CO22 Hepather cohort is sponsored by ANRS. It was financial supported by ANRS, ANR, MSD, Janssen Cilag, Gilead, BMS, Roche, Abbvie and the Direction Générale de la Santé and supported by the Biologic center resources of Hôpital St Antoine, and conducted in collaboration with AFEF INSERM UMR-S 1136 Fabrice Carrat Céline Dorival-Mouly Sandy Lucier Georges Haour Frederic Chau Manon Bergier ANRS Jean-François Delfraissy Ventzislava Petrov Sanchez Mélanie Simony INSERM TRANSFERT Mireille Caralp Françoise Crevel Caroline Moutaudouin- Roy Marion Pirot Sarita Ghanem Elodie Munier Claire Vezier Alpha Diallo Imane Amri Vincent Bonnemains

«I-Reivac» Un réseau d excellence pour la recherche clinique en vaccinologie

«I-Reivac» Un réseau d excellence pour la recherche clinique en vaccinologie «I-Reivac» Un réseau d excellence pour la recherche clinique en vaccinologie I-Reivac Pr Odile Launay Inserm, Université Paris Descartes, AP-HP, Hôpital Cochin, Paris F-CRIN, une infrastructure pour l

More information

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON

More information

MEDICAL POLICY STATEMENT

MEDICAL POLICY STATEMENT MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 5/21/2014 3/24/2016 3/24/2015 Policy Name Policy Number Hepatitis C Oral SRx-0003 Medical Policy Statements

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy

More information

RESEARCH TAX CREDIT. Innovation. Research and development. A comprehensive offering tailored to all your R&D projects.

RESEARCH TAX CREDIT. Innovation. Research and development. A comprehensive offering tailored to all your R&D projects. taxation of R&D RESEARCH TAX CREDIT A comprehensive offering tailored to all your R&D projects Innovation Research and development Tax leveraging Intellectual property Essential ressources serving your

More information

In the case of France, we recognize those higher education institutions that are established or approved by national government authority.

In the case of France, we recognize those higher education institutions that are established or approved by national government authority. COUNTRY-SPECIFIC INFORMATION SHEET FOR FRANCE Universities and Other Higher Education Institutions Recognized in Prince Edward Island (PEI) Only those higher education institutions that are established

More information

Vaccines Researches for the Future:

Vaccines Researches for the Future: ITMO Microbiologie et maladies infectieuses Vaccines Researches for the Future: The corevac initiative Pr Brigitte AUTRAN Institute Infection-Cancer-Immunity, UPMC, Paris Pr Jean François Delfraissy Institute

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Hepatitis C Agents that meet any of the following

More information

1. 2. OUR MISSION SERVIR L AVENIR * OUR EXPERTISE ACCOMPANYING ENTREPRENEURS OUR STRATEGY BRINGING TOGETHER THE BEST OF THE PUBLIC AND PRIVATE SECTORS

1. 2. OUR MISSION SERVIR L AVENIR * OUR EXPERTISE ACCOMPANYING ENTREPRENEURS OUR STRATEGY BRINGING TOGETHER THE BEST OF THE PUBLIC AND PRIVATE SECTORS 1. 2. 3. 4. OUR MISSION SERVIR L AVENIR * OUR EXPERTISE ACCOMPANYING ENTREPRENEURS OUR STRATEGY BRINGING TOGETHER THE BEST OF THE PUBLIC AND PRIVATE SECTORS OUR NETWORK AT THE HEART OF THE REGIONS 3-5

More information

A Cure is Within Reach:

A Cure is Within Reach: A Cure is Within Reach: A Review of the New HCV Medications Misty Miller, Pharm.D., BCPS, AAHIVP Clinical Assistant Professor University of Oklahoma College of Pharmacy September 11, 2015 Pre Assessment

More information

New IDSA/AASLD Guidelines for Hepatitis C

New IDSA/AASLD Guidelines for Hepatitis C NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation

More information

Editorial. Yves Levy, Executive Director

Editorial. Yves Levy, Executive Director Editorial Yves Levy, Executive Director I am delighted to announce the creation of a new research centre: the Vaccine Research Institute (VRI). The VRI addresses the unprecedented challenge of developing

More information

Update on Hepatitis C. Sally Williams MD

Update on Hepatitis C. Sally Williams MD Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;

More information

HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma

HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio

More information

UPDATE ON NEW HEPATITIS C MEDICINES

UPDATE ON NEW HEPATITIS C MEDICINES UPDATE ON NEW HEPATITIS C MEDICINES Diana Sylvestre, MD 2014 AASLD/IDSA Guidelines: Gt 1 Treatment naïve Interferon eligible: sofosuvir + ribavirin + PEG-IFN x 12 weeks Interferon ineligible: sofosbuvir

More information

Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary

Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary This program applies to Health Insurance Marketplace, FlexRx

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hepatitis C Second Generation Antivirals Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Hepatitis C Second Generation Antivirals Through Preferred

More information

PHARMACY PRIOR AUTHORIZATION

PHARMACY PRIOR AUTHORIZATION PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Harvoni (sofosbuvir/ledipasvir), Sovaldi (sofosbuvir), Viekira PAK (ombitsavir, paritapravir/ritonavir, dasubavir), and Olysio (simeprevir) Authorization

More information

France NMO GENERAL INFORMATION

France NMO GENERAL INFORMATION France NMO GENERAL INFORMATION NAME AND COUNTRY France ANEMF LANGUAGE English and for some LC French REQUIRED LANGUAGE At least English, sometimes Frence TIME ZONE (GMT+01:00) Brussels, Copenhagen, Madrid,

More information

The French Higher Education System. Embassy of France in Canada Science and Technology Office http://www.ambafrance-ca.

The French Higher Education System. Embassy of France in Canada Science and Technology Office http://www.ambafrance-ca. he French Higher ducation System mbassy of France in Canada Science and echnology ffice http://www.ambafrance-ca.org/scientific France An age-old university tradition (the University of Paris was founded

More information

Disclosures. Advisory Boards: Speaker Bureaus: Janssen, Gilead, AbbVie. Janssen, Gilead, AbbVie, Bristol-Myers Squibb, Entera Health, Salix

Disclosures. Advisory Boards: Speaker Bureaus: Janssen, Gilead, AbbVie. Janssen, Gilead, AbbVie, Bristol-Myers Squibb, Entera Health, Salix Disclosures Advisory Boards: Janssen, Gilead, AbbVie Speaker Bureaus: Janssen, Gilead, AbbVie, Bristol-Myers Squibb, Entera Health, Salix Outline Assess patient readiness for treatment Examine various

More information

AFEF guidelines Management of hepatitis C virus infection June 2015

AFEF guidelines Management of hepatitis C virus infection June 2015 AFEF guidelines Management of hepatitis C virus infection June 2015 With the support of the SPILF (Société de Pathologie Infectieuse de Langue Française) Chairs Prof. Olivier Chazouillères (APHP Saint-Antoine)

More information

Chronische Hepatitis C. 170 Millionen

Chronische Hepatitis C. 170 Millionen Chronische Hepatitis C 170 Millionen Natürliche Geschichte der Hepatitis C Akute Hepatitis C Chronische Hepatitis C Hepatitis Zirrhose Clearance Zeit (20 Jahre) ist sehr unterschiedlich (Host, Virus, Umwelt)

More information

A Proposal for Managing the Harvoni Wave June 22, 2015

A Proposal for Managing the Harvoni Wave June 22, 2015 A Proposal for Managing the Harvoni Wave June 22, 2015 Clinical Background Hepatitis C is an infectious disease caused by the Hepatitis C Virus (HCV) that damages the liver over time. The disease affects

More information

Journée des Industriels du Réseau TRIGGERSEP

Journée des Industriels du Réseau TRIGGERSEP Journée des Industriels du Réseau TRIGGERSEP Djillali ANNANE Hôpital Raymond Poincaré (AP-HP) Lab Cell Death Inflamation & Infection UMR1173 UVSQ/INSERM Mercredi 3 juin 2015 Institut Pasteur Paris Expertise:

More information

Request for Prior Authorization HEPATITIS C TREATMENTS

Request for Prior Authorization HEPATITIS C TREATMENTS IA Medicaid Member ID # Patient name DOB FAX Completed Form To 1 (800) 574-2515 Provider Help Desk 1 (877) 776-1567 Patient address Patient phone Provider NPI Prescriber name Phone Prescriber address Fax

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hepatitis C Second Generation Antivirals (2015) Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through

More information

PREPARED BY THE CENTER FOR HEALTH LAW AND POLICY INNOVATION OF HARVARD LAW SCHOOL

PREPARED BY THE CENTER FOR HEALTH LAW AND POLICY INNOVATION OF HARVARD LAW SCHOOL Pennsylvania PREPARED BY THE CENTER FOR HEALTH LAW AND POLICY INNOVATION OF HARVARD LAW SCHOOL Pennsylvania Hepatitis C Virus (HCV) in Pennsylvania Prevalence + + Although state-wide data were unavailable,

More information

HEPATITIS C (HCV) CME ACCREDITED INTERACTIVE TRAINING SESSION: @DDW 2015

HEPATITIS C (HCV) CME ACCREDITED INTERACTIVE TRAINING SESSION: @DDW 2015 CME ACCREDITED INTERACTIVE TRAINING SESSION: HEPATITIS C (HCV) @DDW 2015 LIVER DISEASE 905 891 1900 www.careeducation.ca info@careeducation.ca Community Academic Research Education @wearecare CME ACCREDITED

More information

HCERES report on research unit: Under the supervision of the following institutions and research bodies:

HCERES report on research unit: Under the supervision of the following institutions and research bodies: Research units HCERES report on research unit: Cellules Stromales, Homeostasie, Plasticité et Regénération Tissulaire STROMALab Under the supervision of the following institutions and research bodies:

More information

HOTEL PARTICULIER EUROSITES

HOTEL PARTICULIER EUROSITES HOTEL PARTICULIER EUROSITES Presentations CONVENTIONS Annual meetings Workshops Product launches Cocktail parties Receptions TRAININGS L HÔTEL PARTICULIER EUROSITES 7, rue de Liège - 75009 Paris T. : +33

More information

ANDRAL Network: An Open Access Solution for Best Cytological Expertise. www.gfhc-reseau-andral.fr

ANDRAL Network: An Open Access Solution for Best Cytological Expertise. www.gfhc-reseau-andral.fr ANDRAL Network: An Open Access Solution for Best Cytological Expertise www.gfhc-reseau-andral.fr 12 th European Congress on Digital Pathology Paris, June 18-21 th, 2014 Vincent LEYMARIE, Franck TRIMOREAU,

More information

1. 2. OUR MISSION SERVIR L AVENIR * OUR EXPERTISE ACCOMPANYING ENTREPRENEURS OUR STRATEGY BRINGING TOGETHER THE BEST OF THE PUBLIC AND PRIVATE SECTORS

1. 2. OUR MISSION SERVIR L AVENIR * OUR EXPERTISE ACCOMPANYING ENTREPRENEURS OUR STRATEGY BRINGING TOGETHER THE BEST OF THE PUBLIC AND PRIVATE SECTORS SERVIR L AVENIR * 1. 2. 3. 4. OUR MISSION SERVIR L AVENIR * OUR EXPERTISE ACCOMPANYING ENTREPRENEURS OUR STRATEGY BRINGING TOGETHER THE BEST OF THE PUBLIC AND PRIVATE SECTORS OUR NETWORK AT THE HEART

More information

GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION POLICY BRIEF

GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION POLICY BRIEF NEW RECOMMENDATIONS IN THE UPDATED WHO GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION POLICY BRIEF NEW RECOMMENDATIONS IN THE UPDATED WHO GUIDELINES FOR

More information

EASL Recommendations on Treatment of Hepatitis C 2015 SUMMARY

EASL Recommendations on Treatment of Hepatitis C 2015 SUMMARY JULY 2015 EASL Recommendations on Treatment of Hepatitis C 2015 Contents SUMMARY 1. Diagnosis of acute and chronic hepatitis C 2. Screening for chronic hepatitis C 3. Goals and endpoints of HCV therapy

More information

AMSTOUR GOLF PACA 2013 DAMES

AMSTOUR GOLF PACA 2013 DAMES DAMES 1er TOUR 2eme TOUR 3eme TOUR 4eme TOUR 5eme TOUR 6eme TOUR Golf d' AIX EN PROVENCE Golf de l' ECOLE DE L'AIR Golf du LUBERON Golf de LA CABRE D'OR Golf DIGNE LES BAINS Golf SAINTE VICTOIRE GOLF Participants

More information

Integrating Clinical Research in Europe

Integrating Clinical Research in Europe OECD WORKSHOP ON BETTER HEALTH THROUGH BIOMEDICINE INNOVATIVE GOVERNANCE BERLIN, 27-28 SEPTEMBER 2010 Session 2: Streamlining Governance : Towards a more efficient clinical and translational research enterprise

More information

OFSEP, the French MS Registry

OFSEP, the French MS Registry OFSEP, the French MS Registry Dr Eric Van Ganse, Nadine Debard, OFSEP Clinical project manager Overview : OFSEP project OFSEP tools Scientific added value Planned improvements 2 ID CARD NAME OFSEP Nationality

More information

Research units. Laboratory of Microbial Molecular Genetics LMGM

Research units. Laboratory of Microbial Molecular Genetics LMGM Research units HCERES report on research unit: Laboratory of Microbial Molecular Genetics LMGM Under the supervision of the following institutions and research bodies: Université Toulouse 3 - Paul Sabatier

More information

A network of French Universities for engineering

A network of French Universities for engineering A network of French Universities for engineering A national NETWORK of 16 Universities LILLE selected according to their: Top Research Capacities Excellence in Learning Global connections BREST LA ROCHELLE

More information

Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs

Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi

More information

1 st 7 th 2 nd. Our business: to protect your family as well as your private and professional property

1 st 7 th 2 nd. Our business: to protect your family as well as your private and professional property Pacifica Our business: to protect your family as well as your private and professional property PACIFICA IS THE general INSURANCE SUBSIDIARY OF CRÉDIT AGRICOLE ASSURANCES and its ambition is to contribute

More information

Journée des Industriels du Réseau TRIGGERSEP B. François CHU Limoges

Journée des Industriels du Réseau TRIGGERSEP B. François CHU Limoges Journée des Industriels du Réseau TRIGGERSEP B. François CHU Limoges Mercredi 3 juin 2015 Institut Pasteur Paris Why a sepsis network is needed? Sepsis places a burden on the healthcare system: 300 per

More information

Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052)

Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052) Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C PIs: atazanavir PIs: other Simeprevir with ritonavir- or cobicistat boosted PIs (significant simeprevir AUC).

More information

PRIOR AUTHORIZATION POLICY

PRIOR AUTHORIZATION POLICY PRIOR AUTHORIZATION POLICY Harvoni (sofosbuvir/ledipasvir tablets Gilead) To initiate a Coverage Review, Call 1-800-417-1764 OVERVIEW Harvoni is a fixed-dose combination of ledipasvir, a hepatitis C virus

More information

THE VIRAL HEPATITIS CONGRESS 2015. 10 12 September 2015, Kap Europa, Frankfurt, Germany THE VIRAL HEPATITIS CONGRESS. Scientific Programme

THE VIRAL HEPATITIS CONGRESS 2015. 10 12 September 2015, Kap Europa, Frankfurt, Germany THE VIRAL HEPATITIS CONGRESS. Scientific Programme THE VIRAL HEPATITIS CONGRESS THE VIRAL HEPATITIS CONGRESS 2015 10 12 September 2015, Kap Europa, Frankfurt, Germany Scientific Programme PRE-CONGRESS WORKSHOP SPONSOR ACHILLION Achillion is seeking to

More information

METRO : A FREE NEWSPAPER READ IN 130 CITIES OF 23 COUNTRIES

METRO : A FREE NEWSPAPER READ IN 130 CITIES OF 23 COUNTRIES 1 THE STORY METRO : A FREE NEWSPAPER READ IN 130 CITIES OF 23 COUNTRIES 17 million readers : the largest readership in the world. Strengths of Metro The inventor of free newspaper concept. First free newspaper

More information

PLATFORM PARTNERS PARTNERS FOR INTERNATIONAL CLINICAL RESEARCHS

PLATFORM PARTNERS PARTNERS FOR INTERNATIONAL CLINICAL RESEARCHS PLATFORM PARTNERS PARTNERS FOR INTERNATIONAL CLINICAL RESEARCHS Coordonnateurs : Pr Corinne Alberti Pr Éric Vicaut 1 WHO ARE WE? Units of Clinical Research APHP Inserm Partner 2 : Lariboisière Partner

More information

An Approach to the Diagnosis and Treatment of Hepatitis C Virus Infection in 2015. Matthew McMahon, MD

An Approach to the Diagnosis and Treatment of Hepatitis C Virus Infection in 2015. Matthew McMahon, MD An Approach to the Diagnosis and Treatment of Hepatitis C Virus Infection in 2015 Matthew McMahon, MD In the United States, 2.2-3.2 million people are infected with the hepatitis C virus (HCV) Half unaware

More information

Applicable Coding: GCN: Solvaldi - 35708; Harvoni 037179; Viekira Pak 037614; Daklinza 037073, 037074; Technivie - 037844

Applicable Coding: GCN: Solvaldi - 35708; Harvoni 037179; Viekira Pak 037614; Daklinza 037073, 037074; Technivie - 037844 Policy Subject: Policy Number: Classification: Hepatitis C Agents (new) SHS PBD38 Anti-virals: Hepatitis C Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS

More information

Investigation Networks Initiative

Investigation Networks Initiative Investigation Networks Initiative Coordinator, H Decousus, CIC de St Etienne (INSERM CIC1408) Co-coordinator, G Meyer, CIC de Paris HEGP (INSERM CIC 1418) Venous ThromboEmbolism (VTE) Deep vein thrombosis

More information

How can we better treat drug addiction? New scientific and clinical challenges for Europe

How can we better treat drug addiction? New scientific and clinical challenges for Europe December 9th and 10th, 2008 The Grand Amphitheater of the Sorbonne European Conference of Scientific Experts How can we better treat drug addiction? New scientific and clinical challenges for Europe Languages

More information

Current & New Hepatitis C Meds on the Horizon

Current & New Hepatitis C Meds on the Horizon Current & New Hepatitis C Meds on the Horizon African Americans & Clinical Trials National Black Leadership Commission on AIDS May 28, 2014 Tracy Swan, Treatment Action Group Short for.. PEG-IFN pegylated

More information

New All Oral Therapy for Chronic Hepatitis C Virus (HCV): A Cost-Benefit Analysis

New All Oral Therapy for Chronic Hepatitis C Virus (HCV): A Cost-Benefit Analysis New All Oral Therapy for Chronic Hepatitis C Virus (HCV): A Cost-Benefit Analysis Jennifer Orsi, MPH 4 th International Conference on Viral Hepatitis March 17, 2014 2014 Walgreen Co. All rights reserved.

More information

Career Opportunities within the French Alliance for Life and Health Sciences

Career Opportunities within the French Alliance for Life and Health Sciences 1 Career Opportunities within the French Alliance for Life and Health Sciences Mireille Guyader, PhD Director, Inserm-USA Office INSERM KEY FIGURES (Year 2013) Budget: 970 M (~ $1.2 Billion) Human resources:

More information

Co-infected health-care workers

Co-infected health-care workers Co-infected health-care workers Y.Yazdanpanah Service Universitaire des Maladies Infectieuses et du Voyageur C.H. Tourcoing, Faculté de Médecine de Lille CNRS U362, Lille, France Co-infected health-care

More information

Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364

Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364 Daclatasvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364 NICE 2015. All rights reserved. Contents 1 Guidance... 3 Table 1 Daclatasvir

More information

Chronic Hepatitis C Virus (Chronic HCV)

Chronic Hepatitis C Virus (Chronic HCV) Chronic Hepatitis C Virus (Chronic HCV) Amie Baumgartner PA-C Fall 2015 Purpose of Lecture! Educate Gastroenterology nurses about Hepatitis C and its treatment in order to improve their knowledge and confidence

More information

Treatment of Chronic Hepatitis C - September 2015 Update

Treatment of Chronic Hepatitis C - September 2015 Update Treatment of Chronic Hepatitis C - September 2015 Update Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases Written by: Beat Müllhaupt, Andri Rauch, Jan Fehr and Darius

More information

RECOMMENDATIONS FOR THE TREATMENT OF HEPATITIS C

RECOMMENDATIONS FOR THE TREATMENT OF HEPATITIS C PRZEGL EPIDEMIOL 2015; 69: 515-521 Recommendations Polish Group of HCV Experts: Waldemar Halota, Robert Flisiak, Anna Boroń-Kaczmarska, Jacek Juszczyk, Małgorzata Pawłowska, Krzysztof Simon, Krzysztof

More information

Treatment of Chronic Hepatitis C - September 2014 Update

Treatment of Chronic Hepatitis C - September 2014 Update Treatment of Chronic Hepatitis C - September 014 Update Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases Written by: Darius Moradpour, Andri Rauch, Jan Fehr and Beat

More information

Treatment of Hepatitis C in Patients with Renal Insufficiency

Treatment of Hepatitis C in Patients with Renal Insufficiency HEPATITIS WEB STUDY HEPATITIS C ONLINE Treatment of Hepatitis C in Patients with Renal Insufficiency Robert G. Gish MD Professor Consultant, Stanford University Medical Center Senior Medical Director,

More information

Interna'onal congress on Cancer cell death and resistance

Interna'onal congress on Cancer cell death and resistance ! Interna'onal congress on Cancer cell death and resistance May 6 and 7, 2013 h"p://kcelldeath.sciencesconf.org Golf of Seilh Near to Toulouse (Midi-Pyrénées, 31, France) Introduction Content : ² Introduction

More information

Cardiovascular Disease in AIDS

Cardiovascular Disease in AIDS Cardiovascular Disease in AIDS Giuseppe Barbaro - Franck Boccara (Eds) Cardiovascular Disease in AIDS Foreword by W. Rozenbaum 1 3 GIUSEPPE BARBARO Department of Medical Pathophysiology University La Sapienza

More information

Several fibrosis algorithms combining different

Several fibrosis algorithms combining different Comparison of Eight Diagnostic Algorithms for Liver Fibrosis in Hepatitis C: New Algorithms Are More Precise and Entirely Noninvasive Jérôme Boursier, 1,2 Victor de Ledinghen, 3,4 Jean-Pierre Zarski, 5,6

More information

Art and architecture programs in France. Apply online. www.campusart.org

Art and architecture programs in France. Apply online. www.campusart.org CampusArt Art and architecture programs in France Apply online www.campusart.org CampusArt: Mission In partnership with ANdÉA (National association of postsecondary schools of art) and the Ministry of

More information

Rules of the Boiron Frères Young Talent Competition, 2nd Edition

Rules of the Boiron Frères Young Talent Competition, 2nd Edition Rules of the Boiron Frères Young Talent Competition, 2nd Edition Clause 1: Organising Company The Boiron Frères corporate Foundation, called hereafter the Foundation, which is registered office at BP 21016,

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating

More information

Anticipated Date of Discharge Initial Audits

Anticipated Date of Discharge Initial Audits Anticipated Date of Discharge Initial Audits ADOD To follow up on the roll out of the white board documentation of the Anticipated Date of Discharge (ADOD), we have done audits of over 300 white boards

More information

HCERES report on research unit: Under the supervision of the following institutions and research bodies: Biology of Cancer and Infection BCI

HCERES report on research unit: Under the supervision of the following institutions and research bodies: Biology of Cancer and Infection BCI Research units HCERES report on research unit: Biology of Cancer and Infection BCI Under the supervision of the following institutions and research bodies: Université Joseph Fourier - Grenoble - UJF Institut

More information

Positive impact of HCV treatment initiation on health outcomes in injecting drug users

Positive impact of HCV treatment initiation on health outcomes in injecting drug users Positive impact of HCV treatment initiation on health outcomes in injecting drug users Perrine ROUX, PhD Substance Use Research Center, Columbia University, NY Inserm U912, SE4S, Marseille Introduction

More information

Clinical research: overview in France

Clinical research: overview in France Clinical research: overview in France Pr A. Syrota President & CEO Inserm President AVIESAN 1 Clinical research infrastructures : support to investigation and to study management Investigator-driven clinical

More information

Hepatitis C in 2015. Primary Care Providers: Linkage to Care

Hepatitis C in 2015. Primary Care Providers: Linkage to Care Hepatitis C in 2015 Primary Care Providers: Linkage to Care Michael D Voigt Medical Director, Liver Failure and Transplantation University of Iowa, Hospitals and Clinics Disclosures I have NO disclosures

More information

CADTH THERAPEUTIC REVIEW Drugs for Chronic Hepatitis C Infection: Recommendations Report

CADTH THERAPEUTIC REVIEW Drugs for Chronic Hepatitis C Infection: Recommendations Report CADTH THERAPEUTIC REVIEW Drugs for Chronic Hepatitis C Infection: Recommendations Report Product Line: Therapeutic Review Version: 1.0 Volume Number: 3 Issue Number: 1d Publication Date: November 2015

More information

The Walgreens Connected Care SM hepatitis C program: a partnership in putting the patient first

The Walgreens Connected Care SM hepatitis C program: a partnership in putting the patient first The Walgreens Connected Care SM hepatitis C program: a partnership in putting the patient first November 2014 Glen Pietrandoni, RPh, AAHIVP, Walgreens Senior Director, Specialty Products and Services,

More information

CANCER SUMMER SCHOOL 2014 PROGRAM

CANCER SUMMER SCHOOL 2014 PROGRAM CANCER SUMMER SCHOOL 2014 PROGRAM Monday 30 th June 0 Participant Arrival & Coffee Break ED 3 room Presentation of the program Presentation of the participants and of their research interests/experiences

More information

Transmission of HCV in the United States (CDC estimate)

Transmission of HCV in the United States (CDC estimate) Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong

More information

Objectives. Hepatitis C: The new era of screening and treatment. Distribution of HCV genotypes 11/1/2014. History of HCV diagnosis and screening

Objectives. Hepatitis C: The new era of screening and treatment. Distribution of HCV genotypes 11/1/2014. History of HCV diagnosis and screening Objectives Hepatitis C: The new era of screening and treatment David Crabb, M.D. Department of Medicine, Indiana University and Eskenazi Health Describe the natural history of HCV infection Be able to

More information

CORPORATE GOVERNANCE 1.1 CORPORATE GOVERNANCE CODE

CORPORATE GOVERNANCE 1.1 CORPORATE GOVERNANCE CODE CORPORATE GOVERNANCE SINCE ITS CREATION THROUGH A PARTIAL TRANSFER OF AS- SETS BY ELECTRICITÉ DE FRANCE (EDF) ON 1 SEPTEMBER 2005, THE PUBLIC LIMITED COMPANY RTE EDF TRANSPORT (RTE) HAS BEEN ADMINISTERED

More information

Stochastic Methods for the Analysis of NUMerical COdes

Stochastic Methods for the Analysis of NUMerical COdes Stochastic Methods for the Analysis of NUMerical COdes Research group sponsored by the French National Center for Scientific Research aims at coordinating research efforts in developing tools for design,

More information

Ledipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C

Ledipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C Ledipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C Policy Number: Original Effective Date: MM.04.034 12/1/2014 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/1/2014

More information

PRACTICE GUIDANCE Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus

PRACTICE GUIDANCE Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus PRACTICE GUIDANCE Hepatitis C Guidance: AASLD-IDSA s for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus AASLD/IDSA HCV Guidance Panel* Preamble The pace of hepatitis C virus (HCV)

More information

CPE Session 4. Recent Advances in the Journey to Cure Hepatitis C

CPE Session 4. Recent Advances in the Journey to Cure Hepatitis C CPE Session 4 Recent Advances in the Journey to Cure Hepatitis C Friday, April 24, 2015 ACPE UAN 0128-0000-15-024-L01-P 1.0 CPE Hour Jennifer Hickman, PharmD, BCACP Dr. Jennifer Hickman is an ambulatory

More information

EIT Health Jean-Marc Bourez E-Santé Sanofi France Coordinateur Business EIT Health France

EIT Health Jean-Marc Bourez E-Santé Sanofi France Coordinateur Business EIT Health France EIT Health Jean-Marc Bourez E-Santé Sanofi France Coordinateur Business EIT Health France CLC France Accelerator proposal Jean Marc Bourez, SANOFI, Business Creation Coordinator Marc Lemaire, AIR LIQUIDE,

More information

Anniversaires : descendants d'irénée Jean Pharisa

Anniversaires : descendants d'irénée Jean Pharisa Anniversaires : descendants d'irénée Jean Pharisa Valable pour l'année : 2015 Ordre des anniversaires Décès Ordre d'ancienneté Ordre alphabétique Jour Mois Année Personnes Age Dates Jours Age Personnes

More information

Sovaldi (sofosbuvir) Prior Authorization Criteria

Sovaldi (sofosbuvir) Prior Authorization Criteria INITIAL REVIEW CRITERIA Sovaldi (sofosbuvir) Prior Authorization Criteria 1. Adult patient age 18 years old; AND 2. Prescribed by a hepatologist, gastroenterologist, infectious disease specialist, transplant

More information

The French Approach to Rapid Transit Mode Selection and Project Planning Thierry Gouin / Certu

The French Approach to Rapid Transit Mode Selection and Project Planning Thierry Gouin / Certu The French Approach to Rapid Transit Mode Selection and Project Planning Thierry Gouin / Certu Transport Forum / World Bank / Washington / 28 March 2006 The Center for the Study of Urban Planning, Transportation

More information

Call for papers. International Conference of Management

Call for papers. International Conference of Management Call for papers International Conference of Management Governance, Management and Firm Performance in Social and Solidarity Economy. What specificities? Thursday 4 th of November and Friday 5 th of November

More information

HEPATITIS C TREATMENT GUIDELINES

HEPATITIS C TREATMENT GUIDELINES HEPATITIS C TREATMENT GUIDELINES Updated May 21, 2014 INSTRUCTIONS: 1. Review the posted Hepatitis C Treatment Guidelines document to validate that your patient meets the criteria for treatment. 2. Complete

More information

Eradicating HCV: Opportunities and Challenges

Eradicating HCV: Opportunities and Challenges Eradicating HCV: Opportunities and Challenges Andrew Reynolds Hepatitis C Education Manager Project inform Disclosures and a Confession Disclosure I have no financial relationships to disclose and I will

More information

PREDICA Our business: to protect you and your loved ones

PREDICA Our business: to protect you and your loved ones PREDICA Our business: to protect you and your loved ones PREDICA, a CREDIT AGRICOLE ASSURANCES GROUP INSURANCE SUBSIDIARY, is now the nd-biggest life insurer in France. This leading position has been built

More information

Programs of excellence for partner universities. Example of. Network n+i engineering institutes

Programs of excellence for partner universities. Example of. Network n+i engineering institutes Network n+i engineering institutes Programs of excellence for partner universities Example of Network n+i engineering institutes Introducing Network n+i n+i = National + International A network of 50 postgraduate

More information

Student Housing - A Short List

Student Housing - A Short List CBRE France ViewPoint www.cbre.fr/fr_fr/etude March 2012 Student housing in FRANCE David TRAN, Research analyst, Research department SUMMARY In autumn 2011, the French housing stock for students offered

More information

Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365

Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365 Ombitasvir paritaprevir ritonavir with or without dasabuvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365 NICE 2015. All rights reserved.

More information

Clinical case HIV HCV coinfection

Clinical case HIV HCV coinfection Clinical case HIV HCV coinfection Dominique Salmon HUPC, Paris Descartes University PHC, January 2016 Disclosures Board of experts for Gilead and BMS Objectives To discuss: Results of DAA combination in

More information

All hepatitis C medications are specialty products; dispensing is available only via BriovaRx specialty pharmacy.

All hepatitis C medications are specialty products; dispensing is available only via BriovaRx specialty pharmacy. Hepatitis C Medications Prior Authorization Criteria Harvoni (ledipasvir/sofosbuvir), Sovaldi (sofosbuvir), Olysio (simeprevir) #, pegylated interferon (Pegasys & Peg-Intron ), Viekira Pak (ombitasvir/paritaprevir/ritonavir;

More information

Non-invasive evaluation of liver fibrosis: current clinical use and next perspectives (chronic hepatitis C)

Non-invasive evaluation of liver fibrosis: current clinical use and next perspectives (chronic hepatitis C) Non-invasive evaluation of liver fibrosis: current clinical use and next perspectives (chronic hepatitis C) Paul Calès Liver and Gastroenterology department, University hospital & HIFIH laboratory, Angers

More information

Championnat de France Universitaire 2015

Championnat de France Universitaire 2015 Seniors Female A -49 Competitors: 4 (B-12) ANISSA, JEFFALI FRA - C.R. SPORT U. PARIS (R-59) VANESSA, TRUONG FRA - UT2 JEAN JAURES TOULOUSE 106 B-59 (7-8 PTF) FRA - VANESSA 117 59 (3-1 PTF) FRA - VANESSA

More information

Innovations; evolutions of the french system

Innovations; evolutions of the french system Innovations; evolutions of the french system Prof. André Syrota CEO & Chairman, Inserm The biomedical innovation in XXI st century: Challenges, trends, testimonies Chaire d Innovation technologique Liliane

More information